{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:40:39Z","timestamp":1784302839859,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1346-5","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T05:16:26Z","timestamp":1499145386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9072-7128","authenticated-orcid":false,"given":"M.","family":"Schoels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"issue":"2","key":"1346_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","volume":"51","author":"DM Heijde van der","year":"1992","unstructured":"van der Heijde DM, van't Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992;51(2):177\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1346_CR2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1346_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244\u201357.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1346_CR4","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796\u2013806.","journal-title":"Arthritis Res Ther"},{"key":"1346_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1346_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1346_CR7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1346_CR8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","volume":"64","author":"H M\u00e4kinen","year":"2005","unstructured":"M\u00e4kinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005;64(10):1410\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1346_CR9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"DM Heijde van der","year":"2005","unstructured":"van der Heijde DM, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1\u00a0year TEMPO results. Ann Rheum Dis. 2005;64:1582\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1346_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/art.39996","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, Gruben D, et al. Remission Rates with Tofacitinib Treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum. 2016. doi:\n10.1002\/art.39996\n\n [Epub ahead of print].","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1346_CR11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"M Inoue","year":"2007","unstructured":"Inoue M, Yamanaka H, Hara M, et al. Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28 C-reactive protein threshold values. Ann Rheum Dis. 2007;66(3):407\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1346_CR12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3899\/jrheum.091333","volume":"37","author":"I Castrejon","year":"2010","unstructured":"Castrejon I, Ortiz AM, Toledano E, et al. Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol. 2010;37(7):1439\u201343.","journal-title":"J Rheumatol"},{"issue":"6","key":"1346_CR13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis. 2015;74(6):1132\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1346_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","volume":"40","author":"R Fleischmann","year":"2013","unstructured":"Fleischmann R, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40(2):113\u201326.","journal-title":"J Rheumatol"},{"issue":"9617","key":"1346_CR15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987\u201397.","journal-title":"Lancet"},{"key":"1346_CR16","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Anti-rheumatic Drug Therapy study. Arthritis Rheum. 2008;58:2968\u201380.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1346_CR17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","volume":"54","author":"MV Navarro-Compan","year":"2015","unstructured":"Navarro-Compan MV, Gherghe AM, Smolen JS, et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology (Oxford). 2015;54(6):994\u20131007.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1346_CR18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/kel074","volume":"45","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Machold KP, Nell VP, et al. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Rheumatology (Oxford). 2006;45(9):1133\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1346_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/kep442","volume":"49","author":"A Balsa","year":"2010","unstructured":"Balsa A, de Miguel E, Castillo C, et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford). 2010;49(4):683\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1346_CR20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/s10165-010-0328-0","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20(6):539\u201347.","journal-title":"Mod Rheumatol"},{"key":"1346_CR21","first-page":"1015","volume":"35","author":"TS Shaver","year":"2008","unstructured":"Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35:1015\u201322.","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"1346_CR22","first-page":"S334","volume":"64","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Aletaha D, Gruben D, et al. Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheum. 2012;64(Suppl):S334.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1346_CR23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","volume":"71","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1346_CR24","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/art.30634","volume":"63","author":"D Aletaha","year":"2011","unstructured":"Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63(12):3702\u201311.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1346-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T05:16:30Z","timestamp":1499145390000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1346-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1346-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,4]]},"article-number":"155"}}